KOSDAQBiotech & Pharma388610

GFC Life Science

₩3,750▲ 2.04%2026-11-18 close
Market Cap
₩20B
Turnover
₩32,075,764
Volume
8.7K
Shares out.
5.3M
PER
12.9×
PBR
0.7×
EPS
₩328
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

GFC Life Science: Quarterly Profits Hold, Overseas Results Are the Test

GFC Life Science returned to annual net profit in 2025 and its operating profit has risen for three straight quarters through Q3 2026, but how far overseas certifications and exclusive contracts convert into sales remains the key question.

  1. 1

    Revenue rose two straight years, from KRW 15.4 billion in 2023 to KRW 17.7 billion in 2025, and 2025 was the largest year of the three.

  2. 2

    Operating profit fell 77.3% to KRW 386 million in 2025, with higher R&D spending and one-off listing costs cited as the main drivers.

  3. 3

    Q3 2026 revenue of KRW 5.26 billion rose 25.8% year on year, and operating profit of KRW 625 million swung to a profit from a loss a year earlier.

  4. 4

    Overseas sales were about 10% of the total in Q3 2025, and whether certifications in Europe, Japan and the US turn into actual orders is the central test.

  5. 5

    Price-to-book sits below 1x, so the share price trades under the book value of net assets.

02

Business structure

GFC Life Science is a bio-material company founded in 2002 that supplies cosmetic ingredients based on plant cell, skin microbiome and exosome technologies to cosmetic ODM and OEM makers and brand companies in Korea and abroad. The company has said it has developed more than 2,000 bio-cosmetic materials.

The business is split into a materials division and a clinical division. Based on 2024 figures, the materials division generated KRW 12.78 billion, about 76% of the total, and the clinical division generated KRW 4.03 billion, about 24%.

The clinical division provides efficacy testing and claim-substantiation data for functional cosmetics and developed new evaluation methods for wrinkles, pores and pigmentation in 2024.

Skin boosters accounted for about 15% of total revenue in 2025, and the company is widening sales of finished products under its own skin booster brand, GFCCELL EXO.

The medical device business received a manufacturing license in March 2025, and a Class 1 non-sterile medical gel has been cleared, while a Class 2 wound dressing is being prepared for commercialization. Dermal fillers, a Class 4 device, began domestic sales in February 2026.

In March 2026 the company launched its dermo brand fmk and is expanding through online platforms and a large pharmacy chain. Cosmax and Korea Kolmar are cited as customers.

Its technology differentiation rests on exosome and microbiome patent portfolios, and it promotes a model that pairs ingredient supply with clinical evaluation services.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩4.2B-₩300M−6.8%
2025Q4₩4.6B₩79,690,9751.8%
2026Q1₩5B₩500M9.2%
2026Q2₩5.5B₩600M10.6%
2026Q3₩5.3B₩600M11.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩15.4B₩700M₩2.1B4.6%—−1718.9%
2024₩16.8B₩1.7B-₩5.9B10.1%−54.6%84.0%
2025₩17.7B₩400M₩600M2.2%2.3%42.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the basis of the DART-filed figures, annual revenue rose from KRW 15.4 billion in 2023 to KRW 16.8 billion in 2024, up 8.9% year on year, and to KRW 17.7 billion in 2025, up 5.4%, so revenue grew for two straight years with 2025 the largest year of the three.

Operating profit went from KRW 704 million in 2023 to KRW 1.7 billion in 2024, up 142.3%, and then fell to KRW 386 million in 2025, down 77.3%. The company attributed the 2025 decline to higher R&D spending for new products and one-off costs tied to the KOSDAQ transfer listing.

Operating margin was 2.2% in 2025, down from 10.1% in 2024. Net income attributable to controlling shareholders was KRW 2.1 billion in 2023, a net loss of KRW 5.95 billion in 2024 after turning from profit to loss, and KRW 555 million in 2025 after turning back to profit.

Net income including non-controlling interests followed the same path. The company said the 2025 swing to profit reflected lower financial costs, including valuation losses on derivatives linked to convertible preferred shares, so the return to profit rested more on lower financing costs than on core operating gains.

Operating cash flow was KRW 2.27 billion in 2023, KRW 2.97 billion in 2024 and KRW 1.37 billion in 2025.

Quarterly results show an operating loss of KRW 284 million and a controlling-shareholder net loss of KRW 288 million in Q3 2025, followed by an operating profit of KRW 79.69 million in Q4 2025 after the swing to profit.

Operating profit then rose to KRW 464 million in Q1 2026, up 482.3% from the prior quarter, to KRW 581 million in Q2 2026 and to KRW 625 million in Q3 2026, marking three straight quarters of growth. Q3 2026 revenue was KRW 5.26 billion, up 25.8% year on year.

Controlling-shareholder net income, however, peaked at KRW 477 million in Q1 2026 and then fell to KRW 417 million in Q2 and KRW 329 million in Q3, a two-quarter decline. Net income attributable to controlling shareholders over the last four quarters totals KRW 1.69 billion.

The gap in Q3 2026 between rising operating profit and falling net income points to non-operating items and tax as the places to examine.

05

Industry analysis

The cosmetic ingredient industry has grown alongside the expansion of Korean beauty exports, and demand is shifting toward ingredients backed by functional evidence such as papers and clinical data.

Daishin Securities analyzed in a December 2025 report that rising demand for bio-materials underpins the company's earnings normalization.

In April 2026 the company showed its skin longevity platform and plant-derived PDRN material at a major trade show, positioning plant-based sourcing as a point of difference that fits vegan trends.

On regulation, US MoCRA and EU CPNP registration are prerequisites for overseas sales, so the pace of certification determines how fast exports can grow.

In competition, the cosmetic ingredient and ODM market includes many large players, and the company's key customers are among them, which makes material differentiation and evaluation data central to its competitiveness.

The company has proposed bundling ingredient supply with clinical evaluation services, and its clinical unit KDRI is strengthening an exclusive arrangement with a Taiwanese partner and validating test methods with an Indian partner.

Fillers and skin boosters are sold mainly through medical channels such as dermatology and plastic surgery clinics, so their demand structure differs from that of cosmetic ingredients, and the company is pursuing both areas together. Compared with listed peers in cosmetic materials, its revenue scale is on the smaller side.

06

Outlook

The company set an annual revenue target of KRW 23 billion during its 2025 KOSDAQ transfer listing process, but 2025 filed revenue came in at KRW 17.7 billion.

Securities firms had estimated 2025 revenue of about KRW 19.2 billion and operating profit of about KRW 1 billion, while the filed operating profit was KRW 386 million.

The shortfall was attributed to the time from completing overseas product certifications to local partner rollout and then to first purchase orders and revenue recognition, which slipped into 2026. In January 2026 the company said it aimed to add more than ten countries under new exclusive contracts during 2026.

At in-cosmetics Asia 2026 in Bangkok in November 2026, it met new buyers from Vietnam, Japan and the CIS region and discussed 2026 to 2027 local business plans with an existing South American customer. It also discussed exosome and plant-derived PDRN projects with a US distribution partner.

For fillers, the plan for a Class 4 product and in-house production facilities is tied to 2027 approvals and facility completion. In October 2026 the company disclosed a patent decision for a whitening material using miRNA-200c from milk exosomes.

In February 2026 Daishin Securities said it expected operating profit to normalize to at least the 2024 level in 2026. The sequential growth in quarterly operating profit through Q3 2026 points in the same direction.

Whether overseas certifications convert into actual orders will need to be confirmed in upcoming periodic filings and quarterly results.

07

Valuation

PER
12.9×
PBR
0.7×
ROE
6.7%
EPS
₩328
BPS
₩5,757
Dividend per share
₩0

Price-to-book sits below 1x, so the share price trades below the book value of net assets.

The price-to-earnings multiple should be read against the combined controlling-shareholder net income of KRW 1.69 billion over the last four quarters, and because earnings are small, the multiple moves sharply when quarterly net income shifts.

The 2025 return to net profit followed a net loss of KRW 5.95 billion in 2024, so earnings capacity is still in a recovery phase.

At the March 2026 annual general meeting, shareholders approved a capital reserve reduction and a deficit carry-over measure, a procedure that clears accumulated losses and should be viewed separately from shareholder returns.

Dividend payouts are not prominent, so apart from share price movement, shareholder return tools look limited. An analysis at the 2025 listing noted that shares eligible for trading after the offering were 41.3% of total shares, a high proportion at that time.

The direction from losses to profit is confirmed, but because quarterly net income has fluctuated, the multiple should be read together with both the direction and the stability of earnings.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Quarterly profit recovery

Operating profit was KRW 464 million in Q1 2026, up 482.3% from the prior quarter, then rose to KRW 581 million in Q2 and KRW 625 million in Q3, marking three straight quarters of growth. Q3 2026 revenue of KRW 5.26 billion rose 25.8% year on year, so sales growth and margin recovery appeared together. The continuation of profit since the Q4 2025 swing is the core of the bull case.

Overseas certifications and distribution

The company said it obtained EU CPNP certification for four skin booster products in 2025, completed registration with Japan's PMDA, and cleared US MoCRA procedures. It has built an exclusive distribution network across 14 countries and says it exports bio-cosmetic materials to 26 countries.

If partner expansion converts into actual purchase orders, overseas sales could rise well above the roughly 10% share seen in Q3 2025.

Technical evidence and IP

The company said it published seven SCI-level papers in 2025 and filed or registered 18 patents, including on hybrid exosomes. In October 2026 it received a patent decision for a whitening material based on miRNA-200c from milk exosomes and also registered a patent on a skin microbiome strain.

A growing base of functional evidence could serve as a differentiator in customer discussions and overseas certification.

09

Bear factors

Profitability setback

Operating profit fell 77.3% to KRW 386 million in 2025, and operating margin dropped to 2.2% from 10.1% in 2024. R&D spending and one-off listing costs explain part of the decline, but core margins have not returned to the 2024 level.

Controlling-shareholder net income has declined for two straight quarters through Q3 2026, which is a weak point in the recent trend.

Delayed overseas revenue recognition

Against the KRW 23 billion annual revenue target presented during the 2025 listing process, filed 2025 revenue came in at KRW 17.7 billion. Securities analysts attributed the gap to a longer lead time from certification to first orders, which moved into 2026.

While overseas sales stayed around 10% of the total, the effect of overseas expansion has not yet shown clearly in reported results.

Quality of net profit

The company explained that the 2025 swing to net profit reflected lower financial costs, including derivative valuation losses tied to convertible preferred shares. Operating cash flow fell to KRW 1.37 billion in 2025 from KRW 2.97 billion in 2024.

The March 2026 approval of a deficit carry-over measure also shows that profits are still being applied against accumulated losses.

10

Risk factors

Regulatory and overseas registration delays

Overseas sales depend on country-specific sanitary approvals and product registrations. Delays already showed up in 2025 results, so if certification does not lead to partner rollout and orders, revenue recognition slips.

If approval for the Class 4 filler slips from the 2027 plan, the expansion of the medical device business would also be delayed.

Margins and cost structure

R&D and overseas distribution build-out costs were booked in selling and administrative expenses ahead of revenue, so sales growth did not translate directly into profit. The 2.2% operating margin in 2025 illustrates the point. If costs keep rising alongside sales, operating leverage may fail to work as expected.

Capital structure and share supply

The company posted a net loss of KRW 5.95 billion in 2024, and shareholders approved a deficit carry-over in 2026. As of June 2025, borrowings totaled KRW 7.27 billion at interest rates of 3.035% to 5.25%, partly repaid with offering proceeds.

Analysts noted that shares eligible for trading after the offering were 41.3% of the total at listing, which remains a source of share price volatility.

11

What to watch next

  1. End of December 2026

    Whether the company meets its goal of adding more than ten countries under exclusive partner contracts. Contract counts alone matter less than whether first orders and revenue recognition follow.

  2. End of March 2027

    The 2026 annual business report will show full-year revenue, operating margin and overseas sales share. The key question is whether the quarterly operating profit gains carry through to a full-year level near the KRW 1.7 billion recorded in 2024.

  3. Mid-May 2027

    The Q1 2027 quarterly report will show whether overseas orders are reflected in quarterly revenue and how fast filler distribution expands in Korea.

  4. 2027

    Progress on Class 4 filler approval, completion of in-house production facilities and the planned introduction of a pilot fermenter in 2027. These are prerequisites for raising the medical device share of revenue.

12

Overall view

GFC Life Science has grown revenue steadily since 2023, and in 2025 its annual results turned to net profit, helped by lower financial costs. However, operating profit fell to KRW 386 million in 2025 and operating margin was 2.2%, so core profitability has not yet recovered to the 2024 level.

Quarterly revenue and operating profit both rose through 2026, with three straight quarters of operating profit growth, while controlling-shareholder net income has declined for two straight quarters since Q1 2026.

With overseas sales around 10% of the total, whether certifications in Europe, Japan and the US and an exclusive distribution network across 14 countries turn into actual orders will determine the growth path.

In medical devices, fillers began domestic sales in February 2026, and Class 4 approval and in-house production are scheduled for 2027. On valuation, price-to-book is below 1x, but with small earnings the sensitivity of the multiple is high.

The next checkpoints are full-year operating margin and overseas sales share in the 2026 annual report, and whether overseas orders are reflected in revenue in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. sisajournal-e.com
  2. mt.co.kr
  3. m.news.nate.com
  4. kpmg.com
  5. biotimes.co.kr
  6. investnews.co.kr
  7. mt.co.kr
  8. newspim.com
  9. m.news.nate.com
  10. news.nate.com
  11. gfcos.co.kr
  12. newspim.com
  13. m.news.nate.com
  14. m.news.nate.com
  15. medifonews.com
  16. mt.co.kr
  17. mt.co.kr
  18. m.news.nate.com

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis